ArticleMarine drugs2015
Anti-obese effect of glucosamine and chitosan oligosaccharide in high-fat diet-induced obese rats.
Article in Marine drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 137 citations in OpenAlex.
- Effects of Chitosan Oligosaccharide Supplementation on Lipid Profiles in Overweight and Obese Thai Women: A Randomized Controlled Trial.Food science & nutrition · 2025Article
- Improved Enzymatic Properties of Chitosanase CsnMY002 fromInternational journal of molecular sciences · 2025Article
- Synergistic Effects of Chitosan and Fish Oil on Lipid Metabolism in Rats Fed a High-Fat and Low-Carbohydrate Diet.Nutrients · 2024Article
- Effects of Chitosan andBiomedicines · 2024Article
- Effects of Marine Natural Products on Liver Diseases.Marine drugs · 2024Review
- Bioactive carbohydrate polymers from marine sources as potent nutraceuticals in modulating obesity: a review.Food science and biotechnology · 2024Review
- Hypolipidemic Effect of Rice Bran Oil Extract Tocotrienol in High-Fat Diet-Induced Hyperlipidemia Zebrafish (Danio Rerio) Induced by High-Fat Diet.International journal of molecular sciences · 2024Article
- Non-digestible oligosaccharides-based prebiotics to ameliorate obesity: Overview of experimental evidence and future perspectives.Food science and biotechnology · 2023Review
- Anti-Obesity Effects of Chitosan and Its Derivatives.Polymers · 2023Review
- Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms.Scientific reports · 2023Article
- Chitinase-Assisted Bioconversion of Chitinous Waste for Development of Value-Added Chito-Oligosaccharides Products.Biology · 2023Review
- Influence of Degree of Polymerization of Low-Molecular-Weight Chitosan Oligosaccharides on the α-Glucosidase Inhibition.Molecules (Basel, Switzerland) · 2022Article
- Potential Medical Applications of Chitooligosaccharides.Polymers · 2022Review
- Chitosan Oligosaccharide Inhibits the Synthesis of Milk Fat in Bovine Mammary Epithelial Cells through AMPK-Mediated Downstream Signaling Pathway.Animals : an open access journal from MDPI · 2022Article
- Marine Chitooligosaccharide Alters Intestinal Flora Structure and Regulates Hepatic Inflammatory Response to Influence Nonalcoholic Fatty Liver Disease.Marine drugs · 2022Article
- Multiple Roles of Chitosan in Mucosal Drug Delivery: An Updated Review.Marine drugs · 2022Review
- Integrative analysis of multi-omics data to detect the underlying molecular mechanisms for obesity in vivo in humans.Human genomics · 2022Article
- A review on shellfish polysaccharides: Extraction, characterization and amelioration of metabolic syndrome.Frontiers in nutrition · 2022Review
- Heterologous Expression of a Thermostable Chitinase fromFoods (Basel, Switzerland) · 2021Article
- The Role of Chitosan Oligosaccharide in Metabolic Syndrome: A Review of Possible Mechanisms.Marine drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study is to evaluate the anti-obese effects of glucosamine (GLC) and chitosan oligosaccharide (COS) on high-fat diet-induced obese rats.
methodsThe rats were randomly divided into twelve groups: a normal diet group (NF), a high-fat diet group (HF), Orlistat group, GLC high-, middle-, and low-dose groups (GLC-H, GLC-M, GLC-L), COS1 (COS, number-average molecular weight ≤1000) high-, middle-, and low-dose groups (COS1-H, COS1-M, COS1-L), and COS2 (COS, number-average molecular weight ≤3000) high-, middle-, and low-dose groups (COS2-H, COS2-M, COS2-L). All groups received oral treatment by gavage once daily for a period of six weeks.
resultsRats fed with COS1 gained the least weight among all the groups (P < 0.01), and these rats lost more weight than those treated with Orlistat. In addition to the COS2-H and Orlistat groups, the serum total cholesterol (CHO) and low-density lipoprotein cholesterol (LDL-C) levels were significantly reduced in all treatment groups compared to the HF group (P < 0.01). The various doses of GLC, COS1 and COS2 reduced the expression levels of PPARγ and LXRα mRNA in the white adipose tissue.
conclusionsThe results above demonstrated that GLC, COS1, and COS2 improved dyslipidemia and prevented body weight gains by inhibiting the adipocyte differentiation in obese rats induced by a high-fat diet. Thus, these agents may potentially be used to treat obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.